Literature DB >> 22498245

Metabolic insights from extreme human insulin resistance phenotypes.

Anna Stears1, Stephen O'Rahilly, Robert K Semple, David B Savage.   

Abstract

As well as improving diagnostic and clinical outcomes for affected patients, understanding the genetic basis of rare human metabolic disorders has resulted in several fundamental biological insights. In some cases understanding extreme phenotypes has also informed thinking about more prevalent metabolic diseases. Insulin resistance underpins the twin epidemics of obesity and type 2 diabetes as well as accounting for many of the metabolic problems encompassed by the term metabolic syndrome. This review provides a brief update on current understanding of human severe insulin resistance syndromes, before highlighting recent insights provided by studies in these rare syndromes into the molecular pathogenesis of elements of the metabolic syndrome.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498245     DOI: 10.1016/j.beem.2011.09.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  9 in total

Review 1.  Hyperinsulinaemia in cancer.

Authors:  Emily J Gallagher; Derek LeRoith
Journal:  Nat Rev Cancer       Date:  2020-09-09       Impact factor: 60.716

2.  Free fatty acid processing diverges in human pathologic insulin resistance conditions.

Authors:  Hilal Sekizkardes; Stephanie Therese Chung; Shaji Chacko; Morey W Haymond; Megan Startzell; Mary Walter; Peter J Walter; Marissa Lightbourne; Rebecca J Brown
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 3.  Obesity, insulin resistance and comorbidities? Mechanisms of association.

Authors:  Ana Valeria B Castro; Cathryn M Kolka; Stella P Kim; Richard N Bergman
Journal:  Arq Bras Endocrinol Metabol       Date:  2014-08

Review 4.  The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.

Authors:  Gaetano Romano
Journal:  Scientifica (Cairo)       Date:  2013-12-05

5.  Genetic evidence for a normal-weight "metabolically obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes.

Authors:  Hanieh Yaghootkar; Robert A Scott; Charles C White; Weihua Zhang; Elizabeth Speliotes; Patricia B Munroe; Georg B Ehret; Joshua C Bis; Caroline S Fox; Mark Walker; Ingrid B Borecki; Joshua W Knowles; Laura Yerges-Armstrong; Claes Ohlsson; John R B Perry; John C Chambers; Jaspal S Kooner; Nora Franceschini; Claudia Langenberg; Marie-France Hivert; Zari Dastani; J Brent Richards; Robert K Semple; Timothy M Frayling
Journal:  Diabetes       Date:  2014-07-21       Impact factor: 9.337

6.  Effect of Red Orange Juice Consumption on Body Composition and Nutritional Status in Overweight/Obese Female: A Pilot Study.

Authors:  E Azzini; E Venneria; D Ciarapica; M S Foddai; F Intorre; M Zaccaria; F Maiani; L Palomba; L Barnaba; C Tubili; G Maiani; A Polito
Journal:  Oxid Med Cell Longev       Date:  2017-03-20       Impact factor: 6.543

7.  "Treasure Your Exceptions"-Studying Human Extreme Phenotypes to Illuminate Metabolic Health and Disease: The 2019 Banting Medal for Scientific Achievement Lecture.

Authors:  Stephen O'Rahilly
Journal:  Diabetes       Date:  2021-01       Impact factor: 9.461

Review 8.  The Causes of Insulin Resistance in Type 1 Diabetes Mellitus: Is There a Place for Quaternary Prevention?

Authors:  Marta Wolosowicz; Bartlomiej Lukaszuk; Adrian Chabowski
Journal:  Int J Environ Res Public Health       Date:  2020-11-21       Impact factor: 3.390

9.  Truncation of POC1A associated with short stature and extreme insulin resistance.

Authors:  Jian-Hua Chen; Maria Segni; Felicity Payne; Isabel Huang-Doran; Alison Sleigh; Claire Adams; David B Savage; Stephen O'Rahilly; Robert K Semple; Inês Barroso
Journal:  J Mol Endocrinol       Date:  2015-10       Impact factor: 5.098

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.